Time between milestone events in the Alzheimer's disease amyloid cascade

Time between milestone events in the Alzheimer's disease amyloid cascade

Objective: Estimate the time-course of the spread of key pathological markers and the onset of cognitive dysfunction in Alzheimer's disease. Methods: In a cohort of 335 older adults, ranging in cognitive functioning, we estimated the time of initial changes of Aβ, tau, and decreases in cognitio...

Full description

Bibliographic Details
Main Authors:	Philip S. Insel, Michael C. Donohue, David Berron, Oskar Hansson, Niklas Mattsson-Carlgren
Format:	Article
Language:	English
Published:	Elsevier 2021-02-01
Series:	NeuroImage
Subjects:	Alzheimer's disease β-amyloid Tau PET Cognition
Online Access:	http://www.sciencedirect.com/science/article/pii/S1053811920311617

Similar Items

The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study
by: Rola Ismail, et al.
Published: (2020-05-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
by: Philip S. Insel, et al.
Published: (2017-05-01)

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
by: Castillo-Carranza DL, et al.
Published: (2013-12-01)

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
by: Fuyuki Kametani, et al.
Published: (2018-01-01)

Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer’s Disease with APP Osaka Mutation
by: Hiroyuki Shimada, et al.
Published: (2020-06-01)

Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer’s disease
by: Bernard J. Hanseeuw, et al.
Published: (2019-02-01)

Inhibiteurs et modèles moléculaires de fibres amyloïdes ° et tau impliquées dans la maladie d'Alzheimer : conception, synthèse et caractérisation
by: Dufour, Emilie
Published: (2013)

Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease
by: Md. Sahab Uddin, et al.
Published: (2020-08-01)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
by: Dong-Yu Fan, et al.
Published: (2021-01-01)

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
by: Azadeh Firouzian, et al.
Published: (2018-03-01)

Association of Genes Involved in the Metabolic Pathways of Amyloid-β and Tau Proteins With Sporadic Late-Onset Alzheimer’s Disease in the Southern Han Chinese Population
by: Xuewen Xiao, et al.
Published: (2020-11-01)

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
by: Ting-Bin Chen, et al.
Published: (2021-10-01)

Diagnostic biomarkers in Alzheimer’s disease
by: Emerlee Andersen, et al.
Published: (2021-12-01)

Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid
by: Maria-Salud eGarcía-Ayllón, et al.
Published: (2011-09-01)

The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer’s Disease
by: Ling-Yun Fan, et al.
Published: (2018-06-01)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
by: Ashvini Keshavan, et al.
Published: (2020-01-01)

Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET
by: Yu Guo, et al.
Published: (2021-05-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-08-01)

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis
by: Botond Penke, et al.
Published: (2020-04-01)

Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers
by: Petrice M. Cogswell, et al.
Published: (2021-01-01)

Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
by: Min Seok Baek, et al.
Published: (2020-10-01)

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
by: James D. Doecke, et al.
Published: (2020-03-01)

Amyloid Structural Changes Studied by Infrared Microspectroscopy in Bigenic Cellular Models of Alzheimer’s Disease
by: Agnes Paulus, et al.
Published: (2021-03-01)

Alzheimer's amyloid‐β and tau protein accumulation is associated with decreased expression of the LDL receptor‐associated protein in human brain tissue
by: Claire E. Shepherd, et al.
Published: (2020-07-01)

Protein Biomarkers for the Diagnosis of Alzheimer’s Disease at Different Stages of Neurodegeneration
by: Mar Pérez, et al.
Published: (2020-09-01)

Molecular Pathogenesis of Alzheimer’s Disease: Reductionist versus Expansionist Approaches
by: George Perry, et al.
Published: (2009-03-01)

Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer’s Disease
by: Paolo d‘Errico, et al.
Published: (2020-08-01)

Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?
by: Vanessa de Jesus R. de Paula, et al.

Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study
by: Peter Parbo, et al.
Published: (2018-09-01)

The potential value of capsaicin in modulating cognitive functions in a rat model of streptozotocin-induced Alzheimer’s disease
by: Manal A. Shalaby, et al.
Published: (2019-07-01)

Curcuminoids and resveratrol as anti-Alzheimer agents
by: Oliver B. Villaflores, et al.
Published: (2012-12-01)

Clinical Implications of Amyloid-Beta Accumulation in Occipital Lobes in Alzheimer’s Continuum
by: Jihye Hwang, et al.
Published: (2021-09-01)

Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-β and Tau Pathologies
by: Joana R. Guedes, et al.
Published: (2018-08-01)

In Vitro Studies of Flemish, Dutch, and Wild-Type β-Amyloid Provide Evidence for Two-Staged Neurotoxicity
by: Samir Kumar-Singh, et al.
Published: (2002-11-01)

The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome
by: Yvonne S. Davidson, et al.
Published: (2018-07-01)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
by: Jurre den Haan, et al.
Published: (2018-12-01)

Amyloid β and tau pathology in brains of aged pinniped species (sea lion, seal, and walrus)
by: Yuta Takaichi, et al.
Published: (2021-01-01)

Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
by: Tosha Williams, et al.
Published: (2020-01-01)

Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-𝜷 in mild cognitive impairment but not in Alzheimer’s disease
by: Feng Xing, et al.
Published: (2021-06-01)

Cannot write session to /tmp/vufind_sessions/sess_o2j2h05u16drq8e3aqajv3485n